Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis |
| |
Authors: | Yaniv Sherer MD Yehuda Shoenfeld MD |
| |
Institution: | (1) Department of Medicine ‘B’, Sheba Medical Center, 52621 Tel-Hashomer, Israel |
| |
Abstract: | The antiphospholipid syndrome is characterized by arterial and venous thrombosis, as well as pregnancy morbidity, in the presence
of elevated levels of antiphospholipid antibodies. These autoantibodies have procoagulant activity, as they affect platelets,
humoral coagulation factors, and endothelial cells. In addition, they are proatherogenic, as demonstrated by animal models
and by the increased prevalence of cardiovascular diseases in patients with systemic lupus erythematosus and antiphospholipid
syndrome. Moreover, antiphospholipid antibodies, including anticardiolipin, anti-β2-glycoprotein-1, and anti-oxidized low-density
lipoprotein, are associated with atherosclerosis and its consequences in the general population as well. This autoimmune aspect
of atherosclerosis in the presence or absence of an autoimmune disease suggests benefit from development of immunomodulating
therapies. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|